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Colorectal cancer (CRC) caused over 500000 deaths worldwide in 2002. Recent advances in the treatment of advanced disease
include the incorporation of two new cytotoxic agents, irinotecan and oxaliplatin, into first-line regimens. The concept of planned
sequential therapy involving three active agents during the course of a patient’s treatment is evolving. Coupled with the integrated use
of targeted monoclonal antibodies, we can now expect overall survival rates for advanced disease to exceed 20 months. This review
considers current treatments and suggests where future progress may occur.
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Globally, over a million cases of colorectal cancer (CRC) were
reported in 2002 with the incidence approximately balanced
between the sexes. In the same year, over 500000 deaths were
attributed to the disease. There is a 25-fold geographical variation
in incidence, presumably as a consequence of dietary factors, with
the highest rates of occurrence seen in North America, Australia/
New Zealand, Western Europe and in men especially, Japan
(Parkin et al, 2005).
The majority of CRC patients, perhaps 70–80%, present with
apparently resectable localised disease. Surgery, followed by
adjuvant therapy for high-risk patients, will be the optimum
curative treatment approach in such cases. However, ultimately,
approximately half of all diagnosed CRC patients will develop
disseminated advanced disease, which in most cases will be fatal.
Patients with advanced disease who are sufficiently fit usually
receive systemic chemotherapy, first-line, but they may receive
best supportive care, surgery (or in the case of rectal tumours,
radiotherapy) or a combination of these treatments. Their second-
line treatment, if any, is dependent on their response to first-line
treatment, disease status and performance status. Chemotherapy
for advanced disease is an attempt to alleviate and control
symptoms, improve quality of life and improve survival. The aim
of this review is to outline the efficacy and safety data for the
currently available chemotherapy treatment options for patients
with advanced CRC.
CHEMOTHERAPY IN THE TREATMENT OF PATIENTS
WITH ADVANCED CRC
For nearly 50 years, 5-fluorouracil (5-FU) has been the mainstay of
chemotherapy treatment for CRC and fluoropyrimidine-based
chemotherapy remains a key component of the treatment
algorithm for advanced disease, in both the first- and second-
line settings. Indeed, until 10 years ago, 5-FU was the only
chemotherapy option available to patients. Meta-analyses have
shown that chemotherapy for advanced CRC can slow progression
and prolong disease survival compared with best supportive care
(Colorectal Meta-analysis Collaboration, 2000; Simmonds, 2000).
5-FU in combination with the biomodulator folinic acid (FA)
increases the response rate (RR) compared with 5-FU alone (21 vs
11%) and confers a small but significant (11.7 vs 10.5 months)
survival advantage (Thirion et al, 2004). Likewise, 5-FU adminis-
tered as a continuous infusion has superior efficacy when
compared with 5-FU administered as an intravenous (i.v.) bolus
(RR 22 vs 14%) (Meta-analysis Group in Cancer, 1998a).
Furthermore, infusional 5-FU regimens have also been shown to
be associated with fewer World Health Organization grades 3 and 4
toxicities (Meta-analysis Group in Cancer, 1998b). Generally,
physicians in Europe have preferred infusional delivery; with
bolus regimens preferred by physicians in the US. However,
increasingly there is a shift towards the use of infusional regimens
in the US as it is recognised that they are associated not only with a
more manageable toxicity profile but also with increased efficacy.
The dosing schedules for commonly used bolus and infusional
5-FU-based regimens are summarised in Table 1.
The future of 5-FU-based therapy for the treatment of advanced
CRC lies in its combination with newer agents with nonoverlap-
ping toxicity profiles, such as the topoisomerase I inhibitor
irinotecan (CPT11, Campto
s) and the third-generation platinum
compound oxaliplatin (Eloxatin
s). Indeed, the infusional 5-FU
component of current regimens may be replaced in the future by
the new oral fluoropyrimidines, capecitabine (Xeloda
s) and
uracil-tegafur (UFT
s), prodrugs that are designed to mimic
infusional 5-FU treatment (Rich et al, 2004).
Two key studies demonstrated the superior activity of
irinotecan/5-FU/FA compared to 5-FU/FA alone (Douillard et al,
2000; Saltz et al, 2000), leading to the approval of irinotecan for the
first-line treatment of advanced CRC in both the US and Europe in
2000. Likewise, oxaliplatin in combination with infusional 5-FU/FA
was approved for use in the first-line setting in Europe in October
1999 and in the US in combination with 5-FU/FA in January 2004. Received 23 January 2006; revised 29 May 2006; accepted 5 June 2006
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www.bjcancer.comIRINOTECAN IN THE FIRST-LINE TREATMENT OF
ADVANCED CRC
Three published phase III trials evaluated the role of irinotecan
in combination with 5-FU/FA vs 5-FU/FA alone in the first-line
setting. Two European trials investigated infusional 5-FU/FA
regimens (de Gramont and Arbeitsgemeinschaft Internische
Onkologie (AIO)); (Douillard et al, 2000; Ko ¨hne et al, 2005),
whereas a US trial investigated a bolus 5-FU/FA regimen (Saltz
et al, 2000). Irinotecan in combination with the bolus 5-FU/FA
regimen was subsequently shown to be associated with high 60-day
mortality levels (Sargent et al, 2001) and is now generally the less
favoured way of administering this combination.
The addition of irinotecan to 5-FU/FA, irrespective of regimen,
conferred a significant clinical benefit, in terms of RR (35 vs 22, 39
vs 21, 54 vs 32%), progression-free survival (PFS: 6.7 vs 4.4, 7.0 vs
4.3, 8.5 vs 6.4 months) and overall survival (17.4 vs 14.1, 14.8 vs
12.6, 20.1 vs 16.9 months) compared with the corresponding 5-FU/
FA regimen alone (respectively for Douillard et al, 2000; Saltz et al,
2000; Ko ¨hne et al, 2005). Also, although the more recent phase III
study of Ko ¨hne et al, failed to demonstrate a statistically significant
improvement in overall survival, the trend of 43 months increase
led to one of the longest median overall survival times, to date, in
this clinical setting. One can envisage that except for the crossover
to irinotecan-based therapy, second-line, in the control 5-FU/FA
arms of all three trials, these differences might have been even
greater.
The addition of irinotecan to 5-FU/FA did not result in
unacceptable toxicity, although it was associated with a higher
incidence of grade 3 diarrhoea compared with bolus or infusional
5-FU/FA alone. Importantly, some key 5-FU-associated toxicities:
neutropenia, neutropenic fever or sepsis and mucositis were
reduced owing to the lower 5-FU dose administered in the
combination regimens. The time to deterioration in performance
status was also significantly longer for those patients receiving
irinotecan/5-FU/FA (Saltz et al, 2000).
OXALIPLATIN IN THE FIRST-LINE TREATMENT OF
ADVANCED CRC
Published phase III trials similarly reported that in combination
with infusional (de Gramont et al, 2000) or chronomodulated
(Giacchetti et al, 2000) 5-FU/FA, a second new agent, oxaliplatin,
was also effective first-line in the treatment of advanced CRC. RRs
(51 vs 22 and 53 vs 16%, respectively) and median PFS times (9.0 vs
6.2 and 8.7 vs 6.1 months) were improved in the oxaliplatin/5-FU/
FA arms compared to the 5-FU/FA alone arms. The improvements
in these end points were not, however, accompanied by
corresponding significant increases in median overall survival in
the oxaliplatin arms, which may be attributable to the use of active
salvage therapies for both treatment arms in each study.
Although mild gastrointestinal and haematological side effects
are commonly associated with oxaliplatin therapy, the principle
dose-limiting toxicities are neurotoxicity (which may be acute or
chronic) and neutropenia (Grothey and Goldberg, 2004). Acute
neurotoxicity (paresthesias or dysesthesias), although frequently
seen, is generally transient and mild (Gamelin et al, 2002).
However, after several cycles of oxaliplatin therapy, a late-onset
cumulative sensory neuropathy may occur. This side effect
typically improves rapidly with the discontinuation of oxaliplatin
treatment (Grothey, 2003).
RELATIVE EFFICACY OF FIRST-LINE
COMBINATIONS
Comparison of oxaliplatin combined with an infusional 5-FU/FA
regimen (FOLFOX) with irinotecan in combination with bolus
5-FU/FA (IFL) in the US intergroup study (Goldberg et al, 2004)
suggested that the FOLFOX combination was superior in terms of
first-line efficacy. These results formed the basis of the Food and
Drug Administration approval of FOLFOX as a first-line therapy
for advanced CRC in January 2004. However, the bolus 5-FU
component of the IFL regimen is known to be inferior in terms of
efficacy to the infusional 5-FU component of FOLFOX (Meta-
analysis Group in Cancer, 1998a) and so conclusions cannot be
safely drawn from this study concerning relative efficacy of
FOLFOX and irinotecan in combination with infusional 5-FU/FA
(FOLFIRI).
However, the relative efficacy of these two regimens was directly
compared in the randomised Tournigand trial (Tournigand et al,
2004). Although this study was primarily designed to investigate
whether the sequence of administration of FOLFOX and FOLFIRI
was important in terms of second PFS (the time from randomisa-
tion until disease progression after second-line therapy), it
provides an important insight into the relative efficacies of these
combinations in both the first- and second-line settings. Patients
were randomised to one of the two treatment arms. Those in arm A
received FOLFIRI (irinotecan 180mgm
 2 and FA 200mgm
 2 on
day 1, followed by bolus 5-FU 400mgm
 2 and continuous 5-FU,
2400–3000mgm
 2, by 46-h infusion) until disease progression or
unacceptable toxicity, at which time they crossed over to receive
oxaliplatin (100mgm
 2 on day 1) in combination with the same
modified de Gramont (MdG) 5-FU/FA regimen (FOLFOX6).
Conversely, the patients assigned to arm B received FOLFOX6
until disease progression, at which time they crossed over to
receive FOLFIRI.
The median overall survival was 21.5 months for the 109
patients in arm A (FOLFIRI followed by FOLFOX6) and 20.6
months for the 111 patients assigned to arm B (FOLFOX6 followed
by FOLFIRI), leading to the conclusion that the two regimens were
essentially indistinguishable in terms of efficacy. However, it was
noted that a significantly higher number of patients in arm B
had their metastatic disease rendered resectable (P¼0.02). As
expected, the toxicity profiles in first-line therapy of the two
regimens were different, with grade 3/4 mucositis and nausea/
Table 1 Summary of frequently used bolus and infusional 5-FU/FA regimens
Regimens Doses and schedules of administration
Mayo Clinic Regimen (Saltz et al, 2000) 5-FU (425mgm
 2day
 1) i.v. bolus+FA (20mgm
 2day
 1) daily days 1–5 every 4 weeks
Saltz (modified Roswell Park regimen)
(Saltz et al, 2000)
5-FU (500mgm
 2day
 1) i.v. bolus+FA (20mgm
 2day
 1) weekly for 4 weeks every 6 weeks
De Gramont (de Gramont et al, 1997) FA (200mgm
 2) 2h+5-FU (400mgm
 2) i.v. bolus+22h infusion 5-FU (600mgm
 2) for 2 consecutive days every 2 weeks
Modified de Gramont (Leonard et al, 2002) FA (175–200mgm
 2) 2h+5-FU (400mgm
 2) i.v. bolus+46h infusion 5-FU (2400–3000mgm
 2) for 2 consecutive days
every 2 weeks
AIO (Ko ¨hne et al, 2005) 5-FU (2600mgm
 2) 24h CI+FA (500mgm
 2), weekly  6, every 7 or 8 weeks
AIO¼Arbeitsgemeinschaft Internische Onkologie (German Co-operative Group); CI¼continuous infusion; FA¼folinic acid; 5-FU¼5-fluorouracil; i.v.¼intravenous.
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and neurosensory toxicity more frequent with FOLFOX6. In
particular, the number of patients who had to stop oxaliplatin
therapy before tumour resistance owing to neurotoxicity was a
limitation of the study. The most important observation from the
Tournigand study was therefore that median survival was in excess
of 20 months for both arms when the two combinations were used
sequentially (effectively, the use of three active drugs during the
course of the patient’s treatment).
The UK MRC CR08 FOCUS trial was designed to assess the role
of irinotecan or oxaliplatin combined with the modified MdG
infusional 5-FU/FA regimen, in the first- and second-line
treatment of patients with advanced CRC. Patients (2135) with
good performance status were randomly allocated to one of five
treatment arms (Figure 1): staged single-agent therapy (arm A),
staged combination therapy (arms B and D) or first-line
combination therapy (arms C and E). Only slight (nonsignificant)
increases in overall survival were seen with each combination
therapy (hazard ratios: 0.86–0.96) over the staged single-agent arm
(Seymour, 2005). This suggests that staged combination therapy
may provide an alternative treatment strategy for those patients
unable to tolerate first-line combinations.
Interestingly, rather than use of irinotecan- and oxaliplatin-
based regimens sequentially, impressive efficacy data have been
reported from a randomised phase III study in which biweekly
irinotecan, oxaliplatin and infusional 5-FU/FA (FOLFOXIRI) was
compared first-line to FOLFIRI in 244 previously untreated
advanced CRC patients (Falcone et al, 2006). FOLFOXIRI was
assessed as feasible with manageable toxicities. After a median
follow-up of 14 months, RRs were significantly higher (66 vs 41%,
P¼0.0002) and PFS was significantly longer (9.8 vs 6.8 months,
P¼0.0002) in the FOLFOXIRI arm. Full efficacy data are awaited
with interest.
In summary, considering all of the published data and
acknowledging that the side-effect profiles for each drug are
different, it would appear that at least for the moment, a clear case
cannot be made for the preferential use of either irinotecan or
oxaliplatin in first-line combinations (Punt, 2005). However, other
factors such as the relative efficacy of these drugs in the adjuvant
setting might in the future direct which agent is used first-line.
THE INFLUENCE OF SECOND-LINE THERAPY ON
SURVIVAL
The importance of effective second-line therapy was first high-
lighted by the early phase III trials in which single-agent irinotecan
was used as salvage therapy (Cunningham et al, 1998; Rougier
et al, 1998). The FOLFIRI/FOLFOX crossover in the Tournigand
study achieved the longest survival recorded to date, for a phase III
trial in advanced CRC. An interesting question is how much did
crossover therapy contribute to the clinically significant benefits in
survival of over 2–3 months reported for the phase III trials of
irinotecan/5-FU/FA in the first-line setting (Douillard et al, 2000;
Saltz et al, 2000; Ko ¨hne et al, 2005)?
It should be noted that only 50–60% of patients may actually be
well enough to receive such second-line therapy, and consequently,
for a significant number of patients, the choice of an optimum
first-line regimen is critical. However, if we compare the survival
data for trials of irinotecan/5-FU/FA and oxaliplatin 5-FU/FA
combinations (Table 2), we can see that overall survival appears to
increase in proportion to the number of patients who are able to
receive second-line therapy.
Significantly, Grothey and Sargent (2005), in a recent analysis of
21 arms of 11 phase III trials, have shown overall survival to be
significantly correlated with the percentage of patients who
received all three active drugs (irinotecan, oxaliplatin, 5-FU/FA)
during the course of their disease (P¼0.0001), and not simply with
Irinotecan; Ox = Oxaliplatin; Cap = Capecitabine 
Advanced
CRC
Patients
A:MdG until fails Iri
B:MdG until fails Iri+MdG
C:Iri+MdG until fails
D:MdG until fails
MdG Ox Cap
MdG Ox Cap
MdG Ox Cap
Ox + MdG
E:Ox + MdG until fails MdG Iri Cap
MdG Iri Cap
3rd  Drug
Salvage
Randomization
Molecular pathology 
to
find predictive variables:DNA;protein;RNA
Figure 1 Randomisation for the MRC CR08 FOCUS trial.
Table 2 Survival data for patients who received irinotecan/5-FU/FA or oxaliplatin/5-FU/FA combination therapy first-line: influence of second-line therapy
on survival
First-line regimen
Patients receiving
therapy second-line (%)
Patients receiving
three active drugs
a (%) Median OS (months) Study data
Irinotecan+bolus 5-FU/FA 52 5 14.8 Saltz et al (2000)
Irinotecan+bolus 5-FU/FA 67 24 15.0 Goldberg et al (2004)
Irinotecan+inf. 5-FU/FA 39.4 15.7 17.4 Douillard et al (2000)
Irinotecan+AIO 56 52 20.1 Ko ¨hne et al (2005)
Irinotecan+inf. 5-FU/FA 81 74 21.5 Tournigand et al (2004)
FOLFOX 58 29.5 16.2 De Gramont et al
(2000)
FOLFOX 75 60 19.5 Goldberg et al (2004)
FucOX
a NA NA 19.4 Giacchetti et al (2000)
FOLFOX 74 62 20.6 Tournigand et al (2004)
FUFOX (bolus 5-FU/FA
(Mayo Clinic))
81 67.5 20.4 Grothey et al (2004)
AIO¼AIO infusional 5-FU/FA; FA¼folinic acid; 5-FU¼5-fluorouracil; inf¼infusional; OS¼overall survival; NA¼not applicable.
aFUcOX¼chronomodulated 5-FU/FA plus
oxaliplatin.
a(5-FU/FA, irinotecan and oxaliplatin) during first- and second-line treatment.
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chemotherapy (Grothey et al, 2004). Although the first-line use
of a chemotherapy doublet over 5-FU/FA alone was not associated
with a significant efficacy benefit in the expanded analysis
(Grothey and Sargent, 2005), the early use of combination therapy
increases the likelihood that a patient will receive all three active
drugs during their treatment.
HEPATIC RESECTION
Approximately half of CRC patients develop liver metastases
during the course of their disease. Potentially curative surgical
resection of secondary tumours is an option for less than 20% of
such patients. In the remainder, the hepatic lesion is either ill sited,
too large or multinodular, and therefore deemed to be unresect-
able. In a proof-of-principle retrospective study, evaluating a
chronomodulated schedule of 5-FU/FA and oxaliplatin, Giacchetti
et al (1999) demonstrated that first-line cytotoxic chemotherapy
had downsized a significant fraction of unresectable disease to
operability. Specifically, following the treatment of 151 patients
with liver-only, previously inoperable metastatic disease, 77 were
subsequently resected with curative intent. Median overall survival
in this group was 48 months against 15.5 months in the
nonoperated patients.
A recent analysis of all published trials and retrospective studies
that had reported tumour response and resection rates of initially
unresectable hepatic lesions highlighted how effective this
approach can be in advanced CRC. For patients with inoperable
metastases confined to the liver (selected patients), resection rates
after first-line chemotherapy with a range of regimens were 24–
54%, and for all patients with advanced disease (unselected
patients), the rate was 1–26%. A highly significant correlation
between tumour response and resection rates was seen for both
selected and unselected patients, indicating that regimens that
produce the highest RRs are likely to be those that allow the
highest hepatic resection rates (Folprecht et al, 2006). One factor
that should be considered in such evaluations is that a partial
response to treatment is often sufficient and preferable for the
facilitation of potentially curative liver resection.
The recent phase II study of Alberts et al (2005) confirmed the
efficacy of FOLFOX4 in the neoadjuvant setting, with 25 of the 42
(60%) assessable patients with nonoptimally resectable liver-only
metastatic disease showing a reduction of tumour burden and
17 (40%) patients subsequently undergoing surgery following a
median of 6 months of chemotherapy. A high recurrence rate of
71% after a median follow-up of 22 months was observed in this
study for patients who underwent complete resection. It is to be
hoped that the addition of targeted agents to FOLFOX might
further improve efficacy in this setting. Consideration is also being
given to the question of whether perioperative FOLFOX4 is feasible
and clinically effective in the randomised phase III EORTC 40983
study. Early results suggest that such treatment can be adminis-
tered safely and without interfering with the timing of surgery
(Nordlinger et al, 2005). Efficacy data are awaited with interest.
CHOICE OF FIRST-LINE TREATMENT FOLLOWING
ADJUVANT THERAPY
There is, however, a change in the dynamics of the treatment for
CRC emerging. Oxaliplatin/5-FU/FA has been shown to prolong
disease-free survival in patients undergoing curative resection for
stage II and III CRC compared with 5-FU/FA alone (Andre et al,
2004), and has consequently been approved for the adjuvant
therapy of patients with stage III CRC. It is likely that this will in
turn lead to the increased use of irinotecan/5-FU/FA first-line for
advanced disease. This possibility is further strengthened by the
disappointing data from adjuvant therapy trials of irinotecan/5-
FU/FA combinations. In particular, after a median follow-up of 32
months, the PETACC3 study has so far failed to show a statistically
significant survival benefit from adding irinotecan to an infusional
5-FU/FA regimen in stage III colon cancer patients (Van Cutsem
et al, 2005). As oxaliplatin-based combination adjuvant therapy
may be more appropriate for patients with curatively resected
colon cancer, the likelihood of irinotecan being used in the first-
line setting upon relapse is increased. However, if the disease-free
interval is prolonged after oxaliplatin-based adjuvant therapy, then
rechallenging a patient with oxaliplatin when they re-present with
metastatic disease could be considered. However, if a patient is
troubled by persistent neuropathy after adjuvant oxaliplatin, then
it would not be appropriate to reintroduce this agent and therefore
irinotecan-based therapy may be preferred.
ORAL FLUOROPYRIMIDINE THERAPY
It is possible that in the future, the orally active prodrug,
capecitabine, will increasingly replace 5-FU in combined regimens.
Capecitabine is preferentially activated in neoplastic tissue by a
process that exploits the high thymidine phosphorylase enzyme
activity in tumours, thereby providing continuous targeted
fluoropyrimidine exposure without the inconvenience for the
patient of infusional delivery (Rich et al, 2004). Phase III trials in
advanced CRC have shown an improved safety profile over bolus
5-FU/FA (Mayo Clinic regimen) (Van Cutsem et al, 2004a) and a
recent randomised crossover trial has confirmed a high level of
patient preference for oral over i.v. fluoropyrimidine therapy
(Twelves et al, 2006). Capecitabine was also shown in the adjuvant
setting to be at least equivalent in terms of efficacy to bolus 5-FU/
FA, with a significant increase in relapse-free survival in the
capecitabine vs 5-FU/FA group (P¼0.04) (Twelves et al, 2005).
However, one recent report of a randomised phase III trial of first-
line infusional 5-FU/FA/oxaliplatin (FUFOX) vs capecitabine plus
oxaliplatin (CAPOX) has so far failed to exclude the inferiority of
the CAPOX regimen (Kubicka et al, 2006). Indeed, it has been
argued that combinations of capecitabine with oxaliplatin or
irinotecan are currently probably best placed within clinical trial
settings (Ko ¨hne and Folprecht, 2006).
TARGETED AGENTS
As our knowledge of tumour biology and genetics matures, a range
of agents that interact with novel disease-associated targets are
emerging into the clinical setting. Two drugs already approved for
the treatment of CRC are the monoclonal antibodies: cetuximab
(Erbitux
s), which binds to and inhibits activation of the epidermal
growth factor receptor (EGFR) (Li et al, 2005), and bevacizumab
(Avastin
s), which binds vascular endothelial growth factor
(VEGF-A), thereby interfering with signalling through the VEGF-
1 and -2 receptors and inhibiting angiogenesis (Hicklin and Ellis,
2005). Most of the mature data relating to the efficacy of targeted
agents in CRC treatment have been derived using irinotecan
combinations. However, considerable evidence is now emerging
that, as expected, these targeted drugs are not agent specific and
that they are likely to improve the efficacy of both irinotecan and
oxaliplatin combinations.
Cetuximab
Cetuximab has been approved in both Europe and the US for use
in combination with irinotecan as second-line therapy in CRC
patients who have failed prior irinotecan treatment. In the pivotal
study, Cunningham et al (2004) randomised 329 previously treated
patients who had progressed during or immediately following
irinotecan-based therapy into two groups, which received either
cetuximab plus irinotecan (218) or cetuximab (111). They
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median time to progression (4.1 vs 1.5 months) for the
combination therapy group compared to the monotherapy group.
Cetuximab was subsequently investigated first-line in combina-
tion with irinotecan/infusional 5-FU/FA (Rougier et al, 2004;
Folprecht et al, 2006). Initial results showed these combinations
to be safe with promising activity. Early data also suggested that
cetuximab combined with FOLFOX is an active and safe
combination in the first-line treatment of CRC (Polikoff et al,
2005). Indeed, the confirmed RR of 72% to cetuximab/FOLFOX4 in
one first-line phase II trial is one of the highest so far recorded for
this setting and resulted in a resection rate for initially inoperable
metastatic disease of 23% in the unselected patient series (Diaz-
Rubio et al, 2005).
Cetuximab does not appear to increase the intensity or
frequency of the characteristic side effects of cytotoxic chemother-
apy. The most common cetuximab-related adverse event reported
is the development of an acne-like rash. This class effect of EGFR
inhibitors is generally manageable (Segaert et al, 2005) and may be
indicative of a response to cetuximab (Van Cutsem et al, 2004b).
Bevacizumab
Bevacizumab in combination with irinotecan/bolus 5-FU/FA has
been approved for the first-line therapy of patients with advanced
CRC based on the data from the Hurwitz trial (Hurwitz et al, 2004).
Patients in this study (813) were randomised into two groups:
irinotecan/5-FU/FA/bevacizumab (402) vs irinotecan/5-FU/FA plus
placebo (411). There was an improved median duration of survival
(20.3 vs 15.6 months), an increased RR (44.8 vs 34.8%) and a
longer median progression-free survival (10.6 vs 6.2 months) in the
bevacizumab over the placebo arm.
The second-line use of bevacizumab in combination with
oxaliplatin was subsequently explored in the randomised phase
III ECOG 3200 study, which investigated the efficacy and safety
of bevacizumab alone and in combination with FOLFOX4 vs
FOLFOX4 alone in 829 CRC patients previously treated with
irinotecan and a fluoropyrimidine (Giantonio et al, 2005). After a
median follow-up period of 18.7 months, there was a statistically
significant advantage in the bevacizumab/FOLFOX4 arm vs the
FOLFOX arm for both overall survival and PFS (12.5 vs 10.7 and
7.4 vs 5.5 months).
The first-line use of bevacizumab has also been investigated in
the sequential randomised TREE-1 and TREE-2 trials. The TREE-1
study was initially designed to evaluate the efficacy and safety of
three different oxaliplatin and fluoropyrimidine combinations:
FOLFOX, oxaliplatin/bolus 5-FU/FA (bFOL) and capecitabine and
oxaliplatin (CapOx). Following the regulatory approval of bev-
acizumab in 2004, TREE-2 was initiated with the aim of evaluating
the benefits of bevacizumab in combination with the same
regimens. Cross-study comparison suggested that the addition of
bevacizumab improved the RR and median time to progression in
each arm of the study (Hochster et al, 2005, 2006). Overall survival
data are eagerly awaited.
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Figure 2 Expansion of the treatment choices for patients with advanced CRC (Rougier et al, 1998; de Gramont et al, 2000; Douillard et al, 2000;
Maughan et al, 2002; Cunningham et al, 2004; Hurwitz et al, 2004; Tournigand et al, 2004) Iri¼irinotecan; Ox¼oxaliplatin; Cap¼capecitabine;
bev¼bevacizumab; cet¼cetuximab; BSC¼best supportive care.
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gastrointestinal perforation events (Kozloff et al, 2006) and some
concern has been expressed as to whether anti-VEGF therapy
might inhibit wound healing (Scappaticci et al, 2005). This concern
led to the recommendation that a patient should not undergo
elective hepatic resection during or within 8 weeks of bevacizumab
treatment (Ellis et al, 2005).
FUTURE DIRECTIONS: ‘PERSONALISED’ THERAPY
New targeted agents directed against specific proteins and
pathways are likely to continue to improve our ability to treated
advanced CRC. In addition, considerable evidence indicating that
the expression levels or functionality (coding sequence variation)
of certain genes can affect either how a tumour or a patient
responds to a particular drug is also accumulating. Typing such
variation before treatment begins may allow the physician in the
future to select on a case-by-case basis the most appropriate
treatment agents or dose levels (reviewed by Russo et al, 2005). An
example of the potential of this approach is provided by recent
data suggesting that constitutional allelic variation in UDP-
glucuronosyltransferase, a protein involved in the metabolism of
irinotecan, may predict response and toxicity in patients with
advanced CRC treated with capecitabine/irinotecan (Carlini et al,
2005). Prospective studies are clearly required to validate such
observations and to extend their scope to include wider
considerations of other ADME (absorption, distribution, metabo-
lism, excretion) genes, for example, the ATP-binding cassette
transporters, which can contribute to irinotecan efflux (Rhodes
et al, 2005).
The use of such approaches is clearly some way in the future.
However, the strong possibility that the performance of existing
effective treatments might be further improved by the considera-
tion of the genetic background of the patient and/or the genetic/
epigenetic status of the tumour is an enticing prospect. If we are to
realise this potential, the collection and analysis of appropriate
biological material from trial participants needs to be routinely
carried out in current and future studies. Subsequent analyses will
be facilitated by the progressively decreasing costs of genomics
and genotyping technologies.
CONCLUSIONS
The use of irinotecan or oxaliplatin in combination with 5-FU/FA
first-line is consistently associated with a clinically significant
improvement in survival. If oxaliplatin is used more widely in the
adjuvant setting, as seems likely given the data from recent trials,
the use of irinotecan as first-line therapy is likely to increase in the
future. The use of three cytotoxic drugs (irinotecan, oxaliplatin
and 5-FU/FA) during the course of a patient’s treatment has been
shown to maximise survival.
The selection of the optimum treatment regimen for CRC
remains difficult, with a number of effective choices available to
patients and clinicians (Figure 2). The number of such alternatives
is likely to increase over the coming years. Currently, the optimum
first-line approach is to use either FOLFOX or FOLFIRI combined
with a biological agent such as bevacizumab. The alternative
regimen can thereafter be used as second-line treatment, again
combined with a different biological agent, such as cetuximab.
Although maybe not yet seen as an optimal marketing strategy by
the pharmaceutical sector, as our knowledge of predictive tumour
markers increases and as a more diverse range of targeted drugs
becomes available, further dramatic progress in our ability to treat
advanced CRC could lie in a more individualised and scientific
process of treatment selection for the patient.
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